NCT06992115 A Study of the MIND Diet for Persons With Multiple Sclerosis
| NCT ID | NCT06992115 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Condition | Multiple Sclerosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-05-12 |
| Primary Completion | 2029-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-05-12 with a primary completion date of 2029-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will assess the impact of a MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet on brain health and MS symptoms. Participants will be randomly assigned to one of two arms: the diet intervention arm or the "continue current diet"/control arm. Participants randomized to the dietary intervention arm will change their diet to follow a MIND dietary pattern for one year; diet-related education and programming is provided to support this change. Participants randomized to the continue/control arm will be asked to continue their current dietary habits, without major change for one year; multiple sclerosis (MS) MS-related related education and programming (unrelated to diet) is provided. All participants will be asked to provide blood \& stool samples and to complete online questionnaires \& three in-person assessments.
Eligibility Criteria
Inclusion Criteria: * Ages 18-70 years, inclusive * MS diagnosis, on any treatment (including no treatment) * MIND diet score of ≤8 at baseline * NfL parameters determined by age Exclusion Criteria: * Diagnosis of an additional neurodegenerative disease (e.g. Alzheimer's) or other serious neurological condition (e.g. stroke) * Current serious medical condition that could impact the ability to participate or influence study results (e.g. cancer, HIV) * Pregnancy/planning during study period
Contact & Investigator
Ilana B Katz Sand, MD
PRINCIPAL INVESTIGATOR
Icahn School of Medicine at Mount Sinai
Frequently Asked Questions
Who can join the NCT06992115 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06992115 currently recruiting?
Yes, NCT06992115 is actively recruiting participants. Contact the research team at claire.wigley@mssm.edu for enrollment information.
Where is the NCT06992115 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT06992115 clinical trial?
NCT06992115 is sponsored by Icahn School of Medicine at Mount Sinai. The principal investigator is Ilana B Katz Sand, MD at Icahn School of Medicine at Mount Sinai. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.